Stemline Therapeutics, Inc. (NasdaqCM:STML) completed a Follow-on Equity Offering in the amount of $51.8 million. Stemline Therapeutics intend to use the net proceeds from this offering for (i) clinical, regulatory, manufacturing and, if and when approved, potential commercial activities of SL-401; (ii) clinical development of SL-801 and SL-701; (iii) research and development activities; (iv) potential acquisitions and in-licensing; and (v) other general corporate purposes.